PP405
Androgenetic Alopecia (Pattern Hair Loss)
Phase 2aActive
Key Facts
Indication
Androgenetic Alopecia (Pattern Hair Loss)
Phase
Phase 2a
Status
Active
Company
About Pelage Pharmaceuticals
Pelage Pharmaceuticals is an early-stage biotech pioneering a regenerative approach to treating hair loss by targeting the metabolic switch in hair follicle stem cells. Its lead asset, PP405, is a topical small molecule currently in Phase 2a trials for androgenetic alopecia, aiming to reactivate dormant follicles. The company differentiates itself from existing hormonal or poorly understood therapies by focusing on a novel, stem cell-centric mechanism. Backed by a team with strong scientific and clinical dermatology expertise, Pelage seeks to address a large, underserved market with significant unmet need.
View full company profileTherapeutic Areas
Other Androgenetic Alopecia (Pattern Hair Loss) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADA-308 | Aranda Pharma | Pre-clinical |